Bioequivalence revisited: Influence of age and sex on CYP enzymes

被引:115
作者
Bebia, Z
Buch, SC
Wilson, JW
Frye, RF
Romkes, M
Cecchetti, A
Chaves-Gnecco, D
Branch, RA
机构
[1] Univ Pittsburgh, Ctr Clin Pharmacol, Pittsburgh, PA 15219 USA
[2] Univ Pittsburgh, Dept Pharmaceut Sci, Pittsburgh, PA USA
关键词
D O I
10.1016/j.clpt.2004.08.021
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background and Objective: The activity of cytochrome P450 (CYP) enzymes, which determine the rate of elimination of lipid-soluble drugs, demonstrates considerable interindividual variability. The extent to which age and sex influence CYP activity remains unclear in humans. Our objectives were to determine whether in vivo activity of selected CYP enzymes is affected by age or sex and to evaluate sex bioequivalence in a large sample size. Methods. We have assessed in vivo activity of the CYP1A2, 2C19, 2D6, 2E1, and 3A4 enzymes in 161 normal subjects (51% female subjects and 40% aged >50 years). After simultaneous administration of a cocktail of selective probes (caffeine, mephenytoin, debrisoquin [INN, debrisoquine], chlorzoxazone, and dapsone, respectively), phenotypic indices for metabolism of these drugs were used as measures of individual CYP activity. Sex bioequivalence analysis used the bootstrap method. Results. There were no sex differences associated with CYP1A2 activity. A significant negative correlation (r = -0.572, P < .01) between enzyme activity and age was observed for CYP2C19, but there were no sex differences. CYP2D6 activity showed no dependence on age or sex. In contrast, CYP2E1 activity showed an age-associated increase (r = 0.393, P < .01), which developed earlier in life in male subjects compared with female subjects. These results were further supported by the sex bioequivalence analysis of CYP phenotypic activity, which revealed that sexes were equivalent with respect to CYP2C19 (90% confidence interval [CI], 0.874-1.04), CYP3A4 (90% CI, 0.95-1.176), and CYP2D6 (90% CI, 0.928-1.09) phenotype and just exceeded the 0.8 to 1.25 limits to be equivalent with respect to CYP2E1 (90% CI, 0.785-1.08) and CYP1A2 (90% CI, 0.736-1.03) phenotype. Conclusion: These observations suggest that the presence of selective mechanisms of regulation for individual CYP enzymes can be influenced by age and sex. However, we suggest that sex has a limited ability to explain intersubject variation of activity for these phenotypic measures of CYP enzyme activity.
引用
收藏
页码:618 / 627
页数:10
相关论文
共 59 条
[31]   Quantitation of three-month intraindividual variability and influence of sex and menstrual cycle phase on CYP1A2, N-acetyltransferase-2, and xanthine oxidase activity determined with caffeine phenotyping [J].
Kashuba, ADM ;
Bertino, JS ;
Kearns, GL ;
Leeder, JS ;
James, AW ;
Gotschall, R ;
Nafziger, AN .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1998, 63 (05) :540-551
[32]   Quantification of intraindividual variability and the influence of menstrual cycle phase on CYP2D6 activity as measured by dextromethorphan phenotyping [J].
Kashuba, ADM ;
Nafziger, AN ;
Kearns, GL ;
Leeder, JS ;
Shirey, CS ;
Gotschall, R ;
Gaedigk, A ;
Bertino, JS .
PHARMACOGENETICS, 1998, 8 (05) :403-410
[33]   INTERINDIVIDUAL VARIABILITY OF CHLORZOXAZONE 6-HYDROXYLATION IN MEN AND WOMEN AND ITS RELATIONSHIP TO CYP2E1 GENETIC POLYMORPHISMS [J].
KIM, RB ;
OSHEA, D ;
WILKINSON, GR .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1995, 57 (06) :645-655
[34]   Clinical pharmacokinetic considerations in the elderly - An update [J].
Kinirons, MT ;
Crome, P .
CLINICAL PHARMACOKINETICS, 1997, 33 (04) :302-312
[35]   No sex-related differences but significant inhibition by oral contraceptives of CYP2C19 activity as measured by the probe drugs mephenytoin and omeprazole in healthy Swedish white subjects [J].
Laine, K ;
Tybring, G ;
Bertilsson, L .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2000, 68 (02) :151-159
[36]   MENSTRUAL-CYCLE EFFECTS ON CAFFEINE ELIMINATION IN THE HUMAN FEMALE [J].
LANE, JD ;
STEEGE, JF ;
RUPP, SL ;
KUHN, CM .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1992, 43 (05) :543-546
[37]   Cytochrome P450 2E1 activity in diabetic and obese patients as assessed by chlorzoxazone hydroxylation [J].
Lucas, D ;
Farez, C ;
Bardou, LG ;
Vaisse, J ;
Attali, JR ;
Valensi, P .
FUNDAMENTAL & CLINICAL PHARMACOLOGY, 1998, 12 (05) :553-558
[38]   FREQUENCY-DISTRIBUTION OF DAPSONE N-HYDROXYLASE, A PUTATIVE PROBE FOR P4503A4 ACTIVITY, IN A WHITE-POPULATION [J].
MAY, DG ;
PORTER, J ;
WILKINSON, GR ;
BRANCH, RA .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1994, 55 (05) :492-500
[39]   Lack of gender differences and large intrasubject variability in cytochrome P450 activity measured by phenotyping with dextromethorphan [J].
McCune, JS ;
Lindley, C ;
Decker, JL ;
Williamson, KM ;
Meadowcroft, AM ;
Graff, D ;
Sawyer, WT ;
Blough, DK ;
Pieper, JA .
JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 41 (07) :723-731
[40]   Now important are gender differences in pharmacokinetics? [J].
Meibohm, B ;
Beierle, I ;
Derendorf, H .
CLINICAL PHARMACOKINETICS, 2002, 41 (05) :329-342